BetterLife Pharma Inc. (BETR.CN)
CAD 0.09
(-5.26%)
CAD 0.09
(-5.26%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 245.23 Thousand CAD | -44.29% |
| 2022 | 440.17 Thousand CAD | -51.04% |
| 2021 | 899.07 Thousand CAD | 0.0% |
| 2020 | - CAD | -100.0% |
| 2019 | 4.63 Million CAD | 229.02% |
| 2018 | 1.4 Million CAD | 474.03% |
| 2017 | 245.37 Thousand CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.36 Million CAD | -32.89% |
| 2024 Q1 | 1.15 Million CAD | 370.44% |
| 2023 Q4 | 245.23 Thousand CAD | -55.44% |
| 2023 FY | 245.23 Thousand CAD | -44.29% |
| 2023 Q1 | 322.16 Thousand CAD | -26.81% |
| 2023 Q2 | 197.94 Thousand CAD | -38.56% |
| 2023 Q3 | 550.39 Thousand CAD | 178.05% |
| 2022 Q2 | 660.13 Thousand CAD | -12.89% |
| 2022 Q1 | 757.8 Thousand CAD | -15.71% |
| 2022 Q4 | 440.17 Thousand CAD | -22.35% |
| 2022 Q3 | 566.85 Thousand CAD | -14.13% |
| 2022 FY | 440.17 Thousand CAD | -51.04% |
| 2021 Q2 | 71.72 Thousand CAD | -87.42% |
| 2021 Q3 | 73.12 Thousand CAD | 1.96% |
| 2021 Q4 | 899.07 Thousand CAD | 1129.47% |
| 2021 FY | 899.07 Thousand CAD | 0.0% |
| 2021 Q1 | 570.34 Thousand CAD | 0.0% |
| 2020 Q2 | 3.26 Million CAD | -0.25% |
| 2020 FY | - CAD | -100.0% |
| 2020 Q4 | - CAD | -100.0% |
| 2020 Q1 | 3.27 Million CAD | -29.33% |
| 2020 Q3 | 3.25 Million CAD | -0.37% |
| 2019 Q2 | 812.4 Thousand CAD | -5.96% |
| 2019 FY | 4.63 Million CAD | 229.02% |
| 2019 Q4 | 4.63 Million CAD | 496.61% |
| 2019 Q3 | 776.75 Thousand CAD | -4.39% |
| 2019 Q1 | 863.92 Thousand CAD | -38.66% |
| 2018 FY | 1.4 Million CAD | 474.03% |
| 2018 Q4 | 1.4 Million CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 FY | 245.37 Thousand CAD | 0.0% |
| 2017 Q4 | - CAD | -100.0% |
| 2017 Q3 | 259.4 Thousand CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | - CAD | -Infinity% |
| Asep Medical Holdings Inc | - CAD | -Infinity% |
| BioVaxys Technology Corp. | - CAD | -Infinity% |
| ChitogenX Inc. | 3.27 Million CAD | 92.521% |
| Rapid Dose Therapeutics Corp. | 2.12 Million CAD | 88.459% |
| Defence Therapeutics Inc. | 7871.00 CAD | -3015.665% |
| Entheon Biomedical Corp. | - CAD | -Infinity% |
| Gemina Laboratories Ltd. | 205.98 Thousand CAD | -19.056% |
| Glow Lifetech Corp. | - CAD | -Infinity% |
| Lexston Life Sciences Corp. | - CAD | -Infinity% |
| Pharmala Biotech Holdings Inc. | - CAD | -Infinity% |
| Doseology Sciences Inc. | - CAD | -Infinity% |
| MYND Life Sciences Inc. | - CAD | -Infinity% |
| Nova Mentis Life Science Corp. | - CAD | -Infinity% |
| PharmaTher Holdings Ltd. | - CAD | -Infinity% |
| PreveCeutical Medical Inc. | - CAD | -Infinity% |
| Telescope Innovations Corp. | - CAD | -Infinity% |